News & Updates
Filter by Specialty:
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
11 Sep 2022
Spleen pull-out lymph node dissection safe for gastric cancer
The use of spleen pull-out lymph node dissection in the splenic hilum is both safe and feasible for patients with gastric cancer undergoing radical gastrectomy, a recent study has found.
Spleen pull-out lymph node dissection safe for gastric cancer
11 Sep 2022
Trifluridine/tipiracil add-on to bevacizumab safe, effective for mCRC
In patients with metastatic colorectal cancer (mCRC), using trifluridine/tipiracil with bevacizumab is a safe and effective treatment for refractory disease, a recent study has found.
Trifluridine/tipiracil add-on to bevacizumab safe, effective for mCRC
09 Sep 2022
Nine metabolic biomarkers can detect gastric cancer
Gastric cancer (GC) patients show an altered metabolic profile as compared with healthy individuals, a recent China study has found. A biomarker panel monitoring for nine metabolites can facilitate timely detection of GC.
Nine metabolic biomarkers can detect gastric cancer
09 Sep 2022
Incidence of peptic ulcer disease decreasing globally
Peptic ulcer disease (PUD) is still a major cause of hospitalization across the globe, but PUD-related hospitalizations and mortality have been on the decline in many countries belonging to the Organisation for Economic Co-operation and Development (OECD) across Asia, Europe, Oceania, North America, and Latin America, reports a study.
